False Claims By Companies Continue To Give CBD A Bad Name In The Health And Wellness Market
The U.S. Food and Drug Administration (FDA) has issued warning letters to two companies for illegally selling unapproved products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).
According to the FDA, the BIOTA Biosciences and Natures CBD Oil Distribution claimed that their CBD-based products could treat opioid addiction. The company needs to respond to this warning within 15 working days expressing how they plan to fix the violations. Not doing so could result in legal penalties, such as product seizure and/or injunction. Since the opioid crisis in the U.S. is no small issue, misleading claims need to be dealt with properly.
Homero Corp DBA Natures CBD Oil Distribution of New Hampshire received a warning letter for marketing and distributing CBD products as a treatment to opioid addiction as well as other serious diseases. While BIOTA Biosciences, LLC of Washington state also received a warning letter for marketing and distributing injectable CBD products in addition to an injectable curcumin product.
While there have been discussions around THC as a solution to dealing with opioid addicts, there has been no proven studies indicating the same. Moreover, the manufacturing process of these drugs or products is not approved by the FDA either. The agency is concerned that a few people out there could be misled into thinking CBD products could aid their problem and that these products are evaluated and deemed safe by the FDA, which is not the case.
Read Full Article: https://www.greenmarketreport.com
CBD is one of many powerful cannabinoids found in hemp known for helping to support our body and mind. Here at Healing Dragon CBD we do not intend to make unfounded medical claims about the health benefits of CBD. The FDA has not confirmed that CBD cures, treats, or prevents any diseases or conditions. Before reading this article please take a moment to read our full disclosure statement.